These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2893450)

  • 1. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
    Taggart AJ; McDermott B; Delargy M; Elborn S; Forbes J; Roberts SD; Ahnfelt NO
    Scand J Rheumatol Suppl; 1987; 64():29-36. PubMed ID: 2893450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
    Taggart AJ; McDermott BJ; Roberts SD
    Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and synovial fluid concentrations of sulphasalazine and two of its metabolites in rheumatoid arthritis.
    Farr M; Brodrick A; Bacon PA
    Rheumatol Int; 1985; 5(6):247-51. PubMed ID: 2906452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.
    Pullar T; Hunter JA; Capell HA
    Ann Rheum Dis; 1985 Dec; 44(12):831-7. PubMed ID: 2867746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
    Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
    Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.
    Pullar T; Hunter JA; Capell HA
    Br J Rheumatol; 1985 Aug; 24(3):269-76. PubMed ID: 2861876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
    Astbury C; Taggart AJ; Juby L; Zebouni L; Bird HA
    Ann Rheum Dis; 1990 Aug; 49(8):587-90. PubMed ID: 1975737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis.
    Pirmohamed M; Coleman MD; Galvani D; Bucknall RC; Breckenridge AM; Park BK
    Br J Rheumatol; 1993 Mar; 32(3):222-6. PubMed ID: 8095423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which component of sulphasalazine is active in rheumatoid arthritis?
    Pullar T; Hunter JA; Capell HA
    Br Med J (Clin Res Ed); 1985 May; 290(6481):1535-8. PubMed ID: 2860942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment.
    Bax DE; Greaves MS; Amos RS
    Br J Rheumatol; 1986 Aug; 25(3):282-4. PubMed ID: 2873862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.
    Schröder H; Evans DA
    Gut; 1972 Apr; 13(4):278-84. PubMed ID: 4402420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.
    Pullar T; Capell HA
    Drugs; 1986; 32 Suppl 1():54-7. PubMed ID: 2877854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
    Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
    Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of slow-acting antirheumatic drugs.
    Tett SE
    Clin Pharmacokinet; 1993 Nov; 25(5):392-407. PubMed ID: 7904547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
    Teshima D; Hino B; Makino K; Yano T; Itoh Y; Joh Y; Iida M; Oishi R
    J Clin Pharm Ther; 2003 Jun; 28(3):239-42. PubMed ID: 12795783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis.
    Kitas GD; Farr M; Waterhouse L; Bacon PA
    Scand J Rheumatol; 1992; 21(5):220-5. PubMed ID: 1359635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages.
    Wilkieson CA; Madhok R; Hunter JA; Capell HA
    Q J Med; 1993 Aug; 86(8):501-5. PubMed ID: 8105504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.